Novartis | NVS | Long at $99.00As one of the largest pharmaceutical companies in the world, Novartis NYSE:NVS is poised to grow well into 2027. It's trading at a 17x P/E, earnings are forecast to grow 7% per year, it has low debt, and has been raising its dividend over the past few years (3.8%). The price on the daily chart is
Key facts today
Harrow's Nordic Group subsidiary will sell an authorized generic of Maxitrol, an eye treatment developed by Novartis, after acquiring its commercial rights in December 2021.
5.21 CHF
10.52 B CHF
44.31 B CHF
1.69 B
About NOVARTIS N
Sector
Industry
CEO
Vasant Narasimhan
Website
Headquarters
Basel
Founded
1996
ISIN
CH0038459415
FIGI
BBG0027FDTP9
Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment includes researching, distributing and selling patented pharmaceuticals. The Sandoz segment focuses on marketing finished dosage form medicines and intermediary products including active pharmaceutical ingredients. The Corporate segment is involved in group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.
NVS 1H Swing Long Conservative Trend TradeConservative Trend Trade
+ long impulse
+ 1/2 correction
+ T2 level
+ support level
- biggest volume 2Sp-
Calculated affordable stop limit
1 to 2 R/R within 1H range take profit
Daily Trend
"+ long impulse
+ 1/2 correction
+ JOC level
+ support level
- above 1/2 of entire 1D wave at the support le
Investing in Health: Reasons Why Novartis AG Stock Stands OutIn an era where health is wealth, and the global healthcare sector is booming like never before, savvy investors are looking for opportunities that promise growth and a meaningful impact on people’s lives. Enter Novartis AG—a powerhouse in pharmaceuticals that’s not only redefining treatments but al
NVS Novartis AG Options Ahead of EarningsAnalyzing the options chain and the chart patterns of NVS Novartis AG prior to the earnings report this week,
I would consider purchasing the 110usd strike price Calls with
an expiration date of 2024-8-16,
for a premium of approximately $3.30.
If these options prove to be profitable prior to the ear
Novartis Strikes $1.01 Bln Deal with Arvinas for Prostate DrugsNovartis ( NYSE:NVS ), the Swiss pharmaceutical giant, has made a strategic move in the field of cancer treatment by securing a licensing agreement with Arvinas, a U.S. biotech company. The deal, valued at up to $1.01 billion, grants Novartis access to Arvinas' experimental prostate cancer drug, ARV
Investment Opportunity Novartis AG (short)Wyckoff in Daily/Weekly timeframe, we can observe the price took the upside liquidity (bc) before breaking the structure downside.
I'm expecting the price to go back on my grey zone (supply) around 99 before continuing the bearish trend.
First target 88 (sc)
Second target 83 (demand zone)
I will l
Longing Novartis (NVS) Longing Novartis (NVS): A Strategic Investment Amidst Geopolitical Tensions
This article presents a compelling rationale for considering a long position in Novartis (NVS) stock. The primary driving factor behind this investment strategy is Novartis' close association with Sandoz (SDZ) following the
See all ideas
Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
US66989HAS7
NOVARTIS CAP 20/50Yield to maturity
6.91%
Maturity date
Aug 14, 2050
NVS3904288
Novartis Capital Corp. 3.7% 21-SEP-2042Yield to maturity
6.28%
Maturity date
Sep 21, 2042
XPND
NOVARTIS CAPITAL 15/45Yield to maturity
6.06%
Maturity date
Nov 20, 2045
NVS5894401
Novartis Capital Corp. 4.7% 18-SEP-2054Yield to maturity
5.89%
Maturity date
Sep 18, 2054
US66989HAH1
NOVARTIS CAPITAL 14/44Yield to maturity
5.88%
Maturity date
May 6, 2044
NVS5894400
Novartis Capital Corp. 4.2% 18-SEP-2034Yield to maturity
5.06%
Maturity date
Sep 18, 2034
US66989HAR9
NOVARTIS CAP 20/30Yield to maturity
4.80%
Maturity date
Aug 14, 2030
NVS5894399
Novartis Capital Corp. 4.0% 18-SEP-2031Yield to maturity
4.63%
Maturity date
Sep 18, 2031
XPNC
NOVARTIS CAPITAL 15/25Yield to maturity
4.62%
Maturity date
Nov 20, 2025
NVS5894398
Novartis Capital Corp. 3.8% 18-SEP-2029Yield to maturity
4.34%
Maturity date
Sep 18, 2029
US66989HAN8
NOVARTIS CAPITAL 17/27Yield to maturity
4.21%
Maturity date
May 17, 2027
See all NOVNEE bonds
Curated watchlists where NOVNEE is featured.
Related stocks
Frequently Asked Questions
The current price of NOVNEE is 92.47 CHF — it has increased by 1.01% in the past 24 hours. Watch NOVARTIS N 2. LINIE stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on SIX exchange NOVARTIS N 2. LINIE stocks are traded under the ticker NOVNEE.
NOVNEE stock has risen by 1.20% compared to the previous week, the month change is a −7.71% fall, over the last year NOVARTIS N 2. LINIE has showed a 2.65% increase.
NOVNEE reached its all-time high on Jul 20, 2015 with the price of 103.03 CHF, and its all-time low was 47.88 CHF and was reached on Mar 19, 2008. View more price dynamics on NOVNEE chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
NOVNEE stock is 1.49% volatile and has beta coefficient of 0.92. Track NOVARTIS N 2. LINIE stock price on the chart and check out the list of the most volatile stocks — is NOVARTIS N 2. LINIE there?
Today NOVARTIS N 2. LINIE has the market capitalization of 172.49 B, it has increased by 5.27% over the last week.
Yes, you can track NOVARTIS N 2. LINIE financials in yearly and quarterly reports right on TradingView.
NOVNEE net income for the last quarter is 2.47 B CHF, while the quarter before that showed 2.76 B CHF of net income which accounts for −10.52% change. Track more NOVARTIS N 2. LINIE financial stats to get the full picture.
No, NOVNEE doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Apr 24, 2025, the company has 75.88 K employees. See our rating of the largest employees — is NOVARTIS N 2. LINIE on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. NOVARTIS N 2. LINIE EBITDA is 18.90 B CHF, and current EBITDA margin is 42.40%. See more stats in NOVARTIS N 2. LINIE financial statements.
Like other stocks, NOVNEE shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade NOVARTIS N 2. LINIE stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So NOVARTIS N 2. LINIE technincal analysis shows the neutral today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating NOVARTIS N 2. LINIE stock shows the neutral signal. See more of NOVARTIS N 2. LINIE technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.